Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings Inc.

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Harmony Biosciences Holdings yesterday. The company’s shares closed yesterda...

Harmony Biosciences Holdings (HRMY) Receives a Buy from Mizuho Securities

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Harmony Biosciences Holdings. The company’s shares clos...

Truist Financial Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)

Truist Financial analyst Danielle Brill maintained a Buy rating on Harmony Biosciences Holdings today. The company’s shares closed yesterday at $29...

Truist Financial Keeps Their Buy Rating on Harmony Biosciences Holdings (HRMY)

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Harmony Biosciences Holdings, with a price target o...

Current Quarter	$0.79	Next Quarter	$0.91
Current Year	$3.12	Next Year	$3.72
QoQ Growth	+15.2%	YoY Growth	+19.2%
3Y EPS CAGR	+62.2%	Target Price	$45.55
Consensus	Buy	Upside	+32.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HRMY	$34.31	+2.76%	777.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HRMY	$34.31	+2.8%	777.71K
3
4
5
6

HRMY

HRMY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Harmony Biosciences Holdings Inc. Data in Excel

Get Harmony Biosciences Holdings Inc. Data in Excel